Palisade Bio, Inc. Overview
Pro stress-test →Palisade Bio is a clinical-stage biopharmaceutical company developing oral phosphodiesterase-4 (PDE4) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, with its lead candidate PALI-2108 in phase 1b clinical trials to treat inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases through its differentiated prodrug platform and precision pharmacology strategy.
Strategic Profile
Pro stress-test →PALI-2108 is designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. Clinical data from the Phase 1b cohort in moderate-to-severe ulcerative colitis patients showed 100% achieved clinical response and 40% achieved clinical remission, with no serious adverse events; the company is advancing toward Phase 2 clinical studies in UC designed to evaluate clinical remission and response over 12 weeks.
Competitive Landscape
Pro stress-test →Palisade Bio competes in the inflammatory bowel disease therapeutics space against established PDE4 inhibitors and other immunomodulatory agents, positioning PALI-2108 as a novel-formulated alternative with targeted colon delivery and improved tolerability. Competitors include Gilead Sciences (Otezla/apremilast), Pfizer, AbbVie, and other IBD/immunology-focused biopharmaceutical companies developing advanced anti-inflammatory therapeutics.
Industry Context
Palisade Bio, Inc. operates in Specialty biopharmaceuticals for inflammatory bowel disease.
Key facts
Founded: 2001 · Headquarters: Denver, Colorado · Employees: Unknown · Revenue: Minimal (clinical-stage) · Market cap: $311M